论文部分内容阅读
目的探讨沙利度胺联合放射治疗治疗食管癌的临床疗效。方法选取2011年10月至2012年10月期间收治的34例中晚期食管癌患者作为对照组,所有患者均采用单纯放射治疗,回顾性分析其临床资料;选取2012年10月至2013年10月期间采用沙利度胺联合放射治疗治疗的36例中晚期食管癌患者作为试验组,沙利度胺剂量为100 mg/d,睡前顿服,连续1周,如无明显不良反应,则在第2周调整剂量至200~300 mg/d,维持此剂量至第6周,同时给予总剂量为50~60 Gy的放射治疗。比较分析两组患者的生存率、治疗有效率和不良反应的发生率。结果试验组患者的6个月、1年和2年生存率以及治疗有效率均优于对照组,差异有统计学意义(P<0.05)。试验组患者恶性呕吐、便秘、嗜睡无力以及皮疹等不良反应的发生率均低于对照组,差异有统计学意义(P<0.05)。结论沙利度胺联合放射治疗治疗食管癌的临床疗效显著,其不良反应发生率低,安全性高。
Objective To investigate the clinical efficacy of thalidomide combined with radiotherapy in the treatment of esophageal cancer. Methods From October 2011 to October 2012, 34 patients with advanced esophageal cancer were selected as the control group. All patients were treated with radiotherapy alone, and the clinical data were retrospectively analyzed. From October 2012 to October 2013 36 patients with advanced esophageal cancer treated with thalidomide combined with radiotherapy during the trial were treated with thalidomide at a dose of 100 mg daily for 1 week before bedtime and without adverse reactions The second week to adjust the dose to 200 ~ 300 mg / d, to maintain this dose to the sixth week, while giving a total dose of 50 ~ 60 Gy of radiotherapy. Comparative analysis of two groups of patients survival rate, treatment efficiency and incidence of adverse reactions. Results The 6-month, 1-year and 2-year survival rate and the treatment effective rate in the experimental group were significantly higher than those in the control group (P <0.05). The incidence of adverse reactions such as malignant vomit, constipation, lethargy and rash were lower in the test group than in the control group, with significant difference (P <0.05). Conclusion Thalidomide combined with radiotherapy for the treatment of esophageal cancer has a significant clinical effect, with a low incidence of adverse reactions and high safety.